GNBT FB page post: Generex, through NuGenerex I
Post# of 36537
(Total Views: 460)
Posted On: 12/19/2020 12:26:42 PM
GNBT FB page post:
Generex, through NuGenerex Immuno-Oncology, aims to provide long-term vaccine solutions to infectious diseases including #COVID19. In fact, our vaccine platform demonstrated long-term (~80-month) effectiveness and safety in low HER2 expressing and triple-negative #breastcancer in our prior clinical trial. https://bit.ly/3g51QMR
#COVID19 #biotech #coronavirusvaccine #sarscov2 #immunology #immunotherapy #tcells #biotechnology #clinicaltrial #Iikeypeptide
Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence
LINK.SPRINGER.COM
Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence
AE37 and GP2 are HER2
Generex, through NuGenerex Immuno-Oncology, aims to provide long-term vaccine solutions to infectious diseases including #COVID19. In fact, our vaccine platform demonstrated long-term (~80-month) effectiveness and safety in low HER2 expressing and triple-negative #breastcancer in our prior clinical trial. https://bit.ly/3g51QMR
#COVID19 #biotech #coronavirusvaccine #sarscov2 #immunology #immunotherapy #tcells #biotechnology #clinicaltrial #Iikeypeptide
Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence
LINK.SPRINGER.COM
Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence
AE37 and GP2 are HER2
(1)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼